Updated:
Alvogen
Robert Wessman, an Icelandic entrepreneur, founded Alvogen in 2009 as a generic pharmaceutical company.
Alvogen
Robert Wessman, an Icelandic entrepreneur, founded Alvogen in 2009 as a generic pharmaceutical company. The firm grew rapidly through acquisitions and organic development, becoming a top-20 US generic manufacturer by revenue. Wessman, along with co-founder and principal Vikram Shroff, established the family office structure to manage the proceeds from the business, with wealth origin rooted in the pharmaceutical industry. The family office invests primarily in the healthcare and life sciences sectors, targeting specialty pharmaceuticals, generics, and over-the-counter products. Strategy includes direct control investments, licensing deals, and partnership structures. The office has also extended into private credit within healthcare. Geographically, the portfolio spans North America, Europe, and select Asian markets. The office is headquartered in Morristown, New Jersey, and maintains an additional location in New York City. Team size is not publicly disclosed, but the office operates with a lean investment team. No philanthropic foundations or operating companies are disclosed separately from Alvogen's main corporate entity. A structural differentiator is the office's close operational link to the founding pharmaceutical business. Rather than functioning as a pure investment vehicle, the family office often provides strategic capital to the same industry verticals where the principal has deep operating experience. This industry-tied approach gives the office a sourcing advantage in specialty therapeutics and generics.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Morristown
Corporate office
Morristown, NJ, United States
Additional offices
New York, NY, United States
Principals
Robert Wessman
Founder and Chairman
Vikram Shroff
Principal
Sector focus
Frequently asked questions
Who runs investment decisions at Alvogen?
Robert Wessman, founder and chairman, oversees the family office's strategic direction. Vikram Shroff serves as a principal. The office does not publicly disclose a dedicated CIO or investment committee.
How does Alvogen source proprietary deal flow?
The office utilizes industry relationships from its pharmaceutical operating business. Direct sourcing comes through licensing and acquisition opportunities in the generics and specialty therapeutics space.
Is Alvogen structured as a single family office or does it operate more like a venture firm?
Alvogen is a single-family office. It does not accept external capital and concentrates on deploying the wealth generated from the pharmaceutical business. It does not operate as a venture firm with a formal fund structure.
What investment stages does Alvogen typically target?
The office targets control positions in late-stage pharmaceutical assets and specialty companies. It also participates in licensing deals and structured credit arrangements within healthcare.
Where does the underlying wealth come from?
The wealth originates from Robert Wessman's pharmaceutical entrepreneurship, primarily through the growth of Alvogen, which became a top-20 US generic manufacturer. Additional wealth from Vikram Shroff's family is also understood to be part of the office's capital base.
Does Alvogen participate in co-investments alongside external GPs?
Publicly available information does not indicate a pattern of co-investments with external general partners. The office appears to favor direct control investments and does not maintain a publicly stated co-investment program.
Does Alvogen maintain philanthropic structures, and how are they separated?
No separate philanthropic foundation is publicly disclosed for the family office. Robert Wessman has engaged in individual philanthropic activities, but these are not formalized through a specific entity linked to the Alvogen family office.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: